Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
the bull case· 4
11
disclosed supplier and customer relationships documented in SEC filings
sec filingsedgar0.49%
share of a sector ETF's assets representing the largest reported fund weight
n-portJun 30 '264
funds on file reporting positions in the company
n-portas of Jun 30 '26176
portfolio managers reporting positions in institutional regulatory holdings filings
13fJun 30 '26the bear case· 2
6 of 8
recent reports with moves below options implied ranges
earnings historyimplied vs realized2 of 23
among largest reporting managers who reduced their reported stakes last quarter
13fJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 12 '26 report. Not a forecast, not advice.
The one company Capricor Therapeutics, Inc. moves with most closely does not share its SEC classification.
Measured against 209 trading days of our own closes. Co-movement, not cause.
SIC 2834, Pharmaceutical Preparations, from each company's own filings. Largest first.
tall tick = annual report · 1 on record
Capricor Therapeutics is a publicly traded (NASDAQ: CAPR) biotechnology company with a mission to develop groundbreaking therapies that make a meaningful impact on patients’ lives. Capricor is focused on the development of biologics, primarily cell and exosome-based technologies to treat or prevent a broad range of diseases. Our lead product, deramiocel (also referred to as CAP-1002) is a cell therapy designed to treat Duchenne muscular dystrophy (DMD), the most severe form of muscular dystrophy, which results in muscle degeneration and premature death. Capricor’s innovative exosome technology is focusing on engineering exosomes to treat or prevent diseases with high unmet medical needs. Our translational approach to product development is based on the strong research foundation provided by our academic partnerships with leading scientists at top-tier research institutions.
CAPR (Capricor Therapeutics, Inc.) has 4 disclosed suppliers and 7 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.
175 managers report a position worth $1.1B between them, and 23 of them hold 80% of it.
High 9.70 at 4:15 am ET, low 9.01 at 3:30 pm ET.
Capricor Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations